HST Global, Inc. (HSTC) Financial Statements (2024 and earlier)

Company Profile

Business Address 150 RESEARCH DR.
HAMPTON, VA 23666
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1902256601,955 291
Cash and cash equivalents1902256601,955 291
Total current assets:1902256601,955 291
Noncurrent Assets
TOTAL ASSETS:1902256601,955 291
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 7,6953,6564,9183,9103,2284,688
Interest and dividends payable3,6561,014 376,629 
Accrued liabilities 7,695     
Other undisclosed accounts payable and accrued liabilities   3,9043,910(373,401)4,688
Debt     2,957 
Deferred compensation liability     990,000
Due to related parties438,352297,352147,1511,4752,988,128505,959
Other undisclosed current liabilities  1,014 376,6291,692,251
Total current liabilities:446,047301,008153,0835,3853,370,9423,192,898
Noncurrent Liabilities
Total liabilities:446,047301,008153,0835,3853,370,9423,192,898
Equity
Equity, attributable to parent(445,857)(300,783)(152,423)(3,430)(3,370,942)(3,192,607)
Common stock5,2485,2485,2494,24836,72036,720
Additional paid in capital5,417,2365,417,2365,417,2365,358,2362,384,8242,384,824
Accumulated deficit(5,868,341)(5,723,267)(5,574,908)(5,365,914)(5,792,486)(5,614,151)
Total equity:(445,857)(300,783)(152,423)(3,430)(3,370,942)(3,192,607)
TOTAL LIABILITIES AND EQUITY:1902256601,955 291

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(141,035)(145,718)(207,978)(151,554)(142,587)(152,995)
Operating loss:(141,035)(145,718)(207,978)(151,554)(142,587)(152,995)
Nonoperating income (expense)(4,039)(2,642)(1,014)578,126(35,748) 
Interest and debt expense(4,039)(2,642)(1,014)596,00035,74812,097
Income (loss) from continuing operations before equity method investments, income taxes:(149,113)(151,002)(210,006)1,022,572(142,587)(140,898)
Other undisclosed income from continuing operations before income taxes      
Income (loss) from continuing operations before income taxes:(149,113)(151,002)(210,006)1,022,572(142,587)(140,898)
Income tax expense (benefit)  31,15643,888(89,580)37,45056,131
Income (loss) from continuing operations:(149,113)(119,846)(166,118)932,992(105,137)(84,767)
Income (loss) before gain (loss) on sale of properties:(119,846)(166,118)932,992(105,137)(84,767)
Other undisclosed net income (loss)4,039(28,514)(42,874)(506,420)(73,198) 
Net income (loss):(145,074)(148,360)(208,992)426,572(178,335)(84,767)
Other undisclosed net loss attributable to parent      (80,325)
Net income (loss) available to common stockholders, diluted:(145,074)(148,360)(208,992)426,572(178,335)(165,092)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(145,074)(148,360)(208,992)426,572(178,335)(84,767)
Comprehensive income (loss), net of tax, attributable to parent:(145,074)(148,360)(208,992)426,572(178,335)(84,767)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: